NCT00726479

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

A Phase II, Randomised, Double-blind, Placebo-controlled and Parallel Group Study to Evaluate the Safety and Efficacy of Four Weeks Treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) in Patients With COPD Associated With Chronic Bronchitis.

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to investigate the effect of 4-week treatment with 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS and placebo on cough and sputum as determined by the CASA-Q (Cough and Sputum Assessment Questionnaire

Conditions

• Pulmonary Disease, Chronic Obstructive
• Bronchitis, Chronic

Interventions

Type	Name	Description
DRUG	BIBW 2948 BS	7.5 mg b.i.d, 15mg q.d, 15mg b.i.d

Timeline

• Start date: 2008-08-01
• Primary completion: 2008-09-01
• First posted: 2008-08-01
• Last updated: 2014-03-27

Locations

24 sites across 3 countries: United States, France, Germany